製品番号: HY-N7064

Iminostilbene

(別名: 5H-ジベンゾ[b,f]アゼピン)

カスタマーレビュー

Based on 1 Customer Validation

Iminostilbene is a chemical precursor of carbamazepine. Additionally, Iminostilbene is an orally active inhibitor of PKM2 (Pyruvate Kinase M2) and COX2 (Cyclooxygenase-2). Iminostilbene exerts its effects by inhibiting PKM2 and its interaction with HIF-1α and STAT3, reducing COX2 and iNOS expression, and decreasing LPS-induced release of IL-1β, IL-6, TNF-α, and MCP-1, thereby suppressing macrophage-mediated inflammatory responses and improving myocardial ischemia/reperfusion (MI/R) injury. Iminostilbene holds promise for research in inflammation regulation, cardiovascular diseases (such as MI/R injury), and macrophage-mediated immune-related diseases.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.66%
CAS 番号: 256-96-2
分子式: C₁₄H₁₁N
分子量:193.25

保管条件:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Iminostilbene 構造式

CAS 番号: 256-96-2

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 体内実験
化学情報
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target

COX-2

iNOS

STAT3

HIF-1α

TNF Receptor アイソフォーム固有の製品をすべて表示 :

HIF/HIF Prolyl-Hydroxylase アイソフォーム固有の製品をすべて表示 :

STAT アイソフォーム固有の製品をすべて表示 :

Interleukin Related アイソフォーム固有の製品をすべて表示 :

COX アイソフォーム固有の製品をすべて表示 :

NO Synthase アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
U-937	IC₅₀	2.58 μM Compound: 11	Cytotoxicity in UV-irradiated human U937 cells exposed to photosensitizer for 2 hrs before irradiation for 20 mins by WST-1 assay Cytotoxicity in UV-irradiated human U937 cells exposed to photosensitizer for 2 hrs before irradiation for 20 mins by WST-1 assay	[PMID: 24900465]

体外実験

Iminostilbene (2.5-10 μM, 30 h) inhibits LPS-induced inflammatory response, reduces PKM2 expression, and suppresses its downstream signaling pathways in RAW264.7 macrophages^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

LPS (HY-D1056)-induced RAW264.7 macrophages (mouse-derived)
Concentration:

2.5 μM, 5 μM, 10 μM
Incubation Time:

30 h (6 h pre-treatment with Iminostilben, followed by LPS stimulation for 24 h)
Result:

Showed no significant effect on cell viability at low doses, slight reduction at high dose (10 μM).

Real Time qPCR^[2]

Cell Line:

LPS (HY-D1056)-induced RAW264.7 macrophages (mouse-derived)
Concentration:

2.5 μM, 5 μM, 10 μM
Incubation Time:

30 h (6 h pre-treatment with Iminostilben, followed by LPS stimulation for 24 h)
Result:

Suppressed IL-1β, IL-6, MCP-1, and TNF-α mRNA levels.

Western Blot Analysis^[2]

Cell Line:

LPS (HY-D1056)-induced RAW264.7 macrophages (mouse-derived)
Concentration:

2.5 μM, 5 μM, 10 μM
Incubation Time:

30 h (6 h pre-treatment with Iminostilben, followed by LPS stimulation for 24 h)
Result:

Inhibited COX2, PKM2, and iNOS protein expression and reduced PKM2-HIF-1α-STAT3 interaction.

体内実験

Iminostilbene (0.625 mg/kg, 1.25 mg/kg, p.o., once daily for 5 days) improved cardiac function and suppressed inflammation in the myocardial ischemia/reperfusion (MI/R) injury SD rat model^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Myocardial ischemia/reperfusion (MI/R) injury Sprague-Dawley (SD) rat model^[2]
Dosage:

0.625 mg/kg, 1.25 mg/kg
Administration:

Oral gavage (p.o.), once daily for 5 days
Result:

Improved cardiac function, reduced myocardial infarction area.
Decreased CK-MB, LDH, and cTnT levels.
Reduced inflammatory cell infiltration, inhibited COX2 and iNOS expression, and suppressed IL-1β and IL-6 RNA and protein levels.

化学情報

CAS 番号 256-96-2
性状 Solid
分子量 193.25
分子式 C₁₄H₁₁N
Color Yellow to orange
SMILES

C12=CC=CC=C1C=CC3=CC=CC=C3N2
別名

5H-ジベンゾ[b,f]アゼピン
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶剤 & 溶解度

体外:

DMSO : 50 mg/mL (258.73 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

5.1746 mL

25.8732 mL

51.7464 mL

5 mM

1.0349 mL

5.1746 mL

10.3493 mL

10 mM

0.5175 mL

2.5873 mL

5.1746 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (12.94 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (282 KB)
SDS (597 KB)
- English - EN (597 KB)
- Français - FR (597 KB)
- Deutsch - DE (597 KB)
- Norwegian - NO (597 KB)
- Español - ES (597 KB)
- Swedish - SV (597 KB)
- Italian - IT (597 KB)
- Korean - KR (597 KB)
- Portuguese - PT (597 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Christian P, et al. Crystallization of Carbamazepine in Proximity to Its Precursor Iminostilbene and a Silica Surface. Cryst Growth Des. 2016 May 4;16(5):2771-2778. Epub 2016 Mar 30. [Content Brief]

[2]. Lu S, et al. Iminostilbene, a novel small-molecule modulator of PKM2, suppresses macrophage inflammation in myocardial ischemia-reperfusion injury. J Adv Res. 2020 Sep 9;29:83-94. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	5.1746 mL	25.8732 mL	51.7464 mL	129.3661 mL
	5 mM	1.0349 mL	5.1746 mL	10.3493 mL	25.8732 mL
	10 mM	0.5175 mL	2.5873 mL	5.1746 mL	12.9366 mL
	15 mM	0.3450 mL	1.7249 mL	3.4498 mL	8.6244 mL
	20 mM	0.2587 mL	1.2937 mL	2.5873 mL	6.4683 mL
	25 mM	0.2070 mL	1.0349 mL	2.0699 mL	5.1746 mL
	30 mM	0.1725 mL	0.8624 mL	1.7249 mL	4.3122 mL
	40 mM	0.1294 mL	0.6468 mL	1.2937 mL	3.2342 mL
	50 mM	0.1035 mL	0.5175 mL	1.0349 mL	2.5873 mL
	60 mM	0.0862 mL	0.4312 mL	0.8624 mL	2.1561 mL
	80 mM	0.0647 mL	0.3234 mL	0.6468 mL	1.6171 mL
	100 mM	0.0517 mL	0.2587 mL	0.5175 mL	1.2937 mL

Keywords

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Iminostilbene

Apoptosis Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

Metabolism/Protease Compound Library

Stem Cell Signaling Compound Library

Small Molecule Immuno-Oncology Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Glycolysis Compound Library

Pyroptosis Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

FDA Approved & Pharmacopeial Drug Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Antidepressant Compound Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Chemokine Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Cytokine Inhibitors Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Macrophage Related Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library

Drug Fragment Library

TNF Receptor アイソフォーム固有の製品をすべて表示

HIF/HIF Prolyl-Hydroxylase アイソフォーム固有の製品をすべて表示

STAT アイソフォーム固有の製品をすべて表示

Interleukin Related アイソフォーム固有の製品をすべて表示

COX アイソフォーム固有の製品をすべて表示

NO Synthase アイソフォーム固有の製品をすべて表示

生物活性

化学情報

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Iminostilbene 関連分類

HY-N7064 関連分類